SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-134402
Filing Date
2023-05-03
Accepted
2023-05-03 16:11:00
Documents
12
Period of Report
2023-05-01
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d276635d8k.htm   iXBRL 8-K 22328
  Complete submission text file 0001193125-23-134402.txt   147061

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA stsa-20230501.xsd EX-101.SCH 2855
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE stsa-20230501_lab.xml EX-101.LAB 18736
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stsa-20230501_pre.xml EX-101.PRE 11710
6 EXTRACTED XBRL INSTANCE DOCUMENT d276635d8k_htm.xml XML 3448
Mailing Address 4819 EMPEROR BOULEVARD SUITE 340 DURHAM NC 27703
Business Address 4819 EMPEROR BOULEVARD SUITE 340 DURHAM NC 27703 415-505-0809
Satsuma Pharmaceuticals, Inc. (Filer) CIK: 0001692830 (see all company filings)

IRS No.: 813039831 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39041 | Film No.: 23883821
SIC: 2834 Pharmaceutical Preparations